PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.

@article{Pan2015PLGApoloxamerNL,
  title={PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.},
  author={Xinting Pan and Qingyun Zhu and Yunbo Sun and Liandi Li and Yunpeng Zhu and Zhihui Zhao and Jianxin Zuo and W. J. Fang and Kun Tze Li},
  journal={International journal of molecular medicine},
  year={2015},
  volume={35 4},
  pages={995-1002}
}
Endothelial PAS domain protein 1 (EPAS1) is a hypoxia-inducible protein that contributes to tumor progression. Hypoxia is involved in tumor aggressiveness and resistance to chemotherapy and ionizing radiation. In this study, we aimed to assess the effects of EPAS1 silencing using polyethylenimine-poly(lactide-coglycolide) (PLGA)/poloxamer nanoparticles loaded with EPAS1 siRNA on BxPC-3 pancreatic cancer cells and in a mouse model of ectopic pancreatic cancer. PLGA/poloxamer nanoparticles loaded… CONTINUE READING